The changing prevalence of pulmonary infection in adults with cystic fibrosis: A longitudinal analysis

Journal of Cystic Fibrosis

Volumn 16, Issue 1, 2017, Pages 70-77

  Ramsay, Kay A ^a,b   Sandhu, Harpreet ^c   Geake, James B ^d,e   Ballard, Emma ^a   O'Rourke, Peter ^a   Wainwright, Claire E ^b,f   Reid, David W ^a,g   Kidd, Timothy J ^b,h   Bell, Scott C ^a,b,g  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c GREAT WESTERN HOSPITAL   (United Kingdom)

^d ROYAL ADELAIDE HOSPITAL   (Australia)

^e LYELL MCEWIN HOSPITAL   (Australia)

^f LADY CILENTO CHILDREN S HOSPITAL   (Australia)

^g THE PRINCE CHARLES HOSPITAL   (Australia)

^h QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

Lung function; Paediatric; Prevalence; Pseudomonas aeruginosa; Transition

Indexed keywords

ANTIBIOTIC AGENT; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; ANTIINFECTIVE AGENT;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; ASPERGILLUS; BRONCHOSCOPY; BURKHOLDERIA CEPACIA COMPLEX; CYSTIC FIBROSIS; FEMALE; HUMAN; LUNG FUNCTION; LUNG INFECTION; LUNG TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; NUTRITIONAL STATUS; PANCREATIC INSUFFICIENCY; PREVALENCE; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS PNEUMONIA; SPUTUM ANALYSIS; STAPHYLOCOCCUS AUREUS; TRANSITION TO ADULT CARE; ADOLESCENT; AUSTRALIA; BURKHOLDERIA INFECTION; ISOLATION AND PURIFICATION; LONGITUDINAL STUDY; LUNG FUNCTION TEST; MICROBIOLOGY; PROCEDURES; PSEUDOMONAS INFECTION; RESPIRATORY TRACT INFECTION; SPUTUM; STAPHYLOCOCCUS INFECTION; STATISTICS AND NUMERICAL DATA;

ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; AUSTRALIA; BURKHOLDERIA CEPACIA COMPLEX; BURKHOLDERIA INFECTIONS; CYSTIC FIBROSIS; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; PREVALENCE; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RESPIRATORY FUNCTION TESTS; RESPIRATORY TRACT INFECTIONS; SPUTUM; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; TRANSITION TO ADULT CARE;

EID: 84995603584     PISSN: 15691993     EISSN: 18735010     Source Type: Journal    
DOI: 10.1016/j.jcf.2016.07.010     Document Type: Article

References (36)

1. [1] O'Sullivan, B.P., Freedman, S.D., Cystic fibrosis. Lancet 373:9678 (2009), 1891–1904.
2. [2] Ratjen, F., Munck, A., Kho, P., Angyalosi, G., Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: the ELITE trial. Thorax 65:4 (2010), 286–291.
3. [3] Chmiel, J.F., Aksamit, T.R., Chotirmall, S.H., Dasenbrook, E.C., Elborn, J.S., LiPuma, J.J., et al. Antibiotic management of lung infections in cystic fibrosis. I. The microbiome, methicillin-resistant Staphylococcus aureus, gram-negative bacteria, and multiple infections. Ann Am Thorac Soc 11:7 (2014), 1120–1129.
4. [4] Lipuma, J.J., The changing microbial epidemiology in cystic fibrosis. Clin Microbiol Rev 23:2 (2010), 299–323.
5. [5] Spicuzza, L., Sciuto, C., Vitaliti, G., Di Dio, G., Leonardi, S., La Rosa, M., Emerging pathogens in cystic fibrosis: ten years of follow-up in a cohort of patients. Eur J Clin Microbiol Infect Dis 28:2 (2009), 191–195.
6. [6] Valenza, G., Tappe, D., Turnwald, D., Frosch, M., Konig, C., Hebestreit, H., et al. Prevalence and antimicrobial susceptibility of microorganisms isolated from sputa of patients with cystic fibrosis. J Cyst Fibros 7:2 (2008), 123–127.
7. [7] Salsgiver, E.L., Fink, A.K., Knapp, E.A., LiPuma, J.J., Olivier, K.N., Marshall, B.C., et al. Changing epidemiology of the respiratory bacteriology of patients with cystic fibrosis. Chest 149:2 (2016), 390–400.
8. [8] Doring, G., Flume, P., Heijerman, H., Elborn, J.S., Treatment of lung infection in patients with cystic fibrosis: current and future strategies. J Cyst Fibros 11:6 (2012), 461–479.
9. [9] Langton Hewer, S.C., Smyth, A.R., Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis. Cochrane Database Syst Rev, 11, 2014, Cd004197.
10. [10] Mayer-Hamblett, N., Kloster, M., Rosenfeld, M., Gibson, R.L., Retsch-Bogart, G.Z., Emerson, J., et al. Impact of sustained eradication of new Pseudomonas aeruginosa infection on long-term outcomes in cystic fibrosis. Clin Infect Dis 61:5 (2015), 707–715.
11. [11] Razvi, S., Quittell, L., Sewall, A., Quinton, H., Marshall, B., Saiman, L., Respiratory microbiology of patients with cystic fibrosis in the United States, 1995 to 2005. Chest 136:6 (2009), 1554–1560.
12. [12] UK CF Database, Cystic Fibrosis Trust, Annual Data Report 2004. http://www.cysticfibrosis.org.uk/media/82427/CR_Annual_Data_Report_2004_06.pdf, 2006.
13. [13] UK Cystic Fibrosis Registry, 2014 Annual Data Report. http://www.cysticfibrosis.org.uk/research-care/uk-cf-registry/cf-registry-reports, 2015.
14. [14] Millar, F.A., Simmonds, N.J., Hodson, M.E., Trends in pathogens colonising the respiratory tract of adult patients with cystic fibrosis, 1985–2005. J Cyst Fibros 8:6 (2009), 386–391.
15. [15] Cystic Fibrosis Australia 2013. 16th Annual Report from the Cystic Fibrosis Data Registry, 2015 [http://www.cysticfibrosis.org.au/cfa/data-registry].
16. [16] Cystic Fibrosis Foundation Patient Registry, 2014 Annual Data Report to the Center Directors. 2015, Cystic Fibrosis Foundation, Bethesda, Maryland [www.cff.org/Our-Research/CF-Patient-Registry/].
17. [17] Emerson, J., Rosenfeld, M., McNamara, S., Ramsey, B., Gibson, R.L., Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr Pulmonol 34:2 (2002), 91–100.
18. [18] Lee, T.W., Brownlee, K.G., Conway, S.P., Denton, M., Littlewood, J.M., Evaluation of a new definition for chronic Pseudomonas aeruginosa infection in cystic fibrosis patients. J Cyst Fibros 2:1 (2003), 29–34.
19. [19] Pressler, T., Bohmova, C., Conway, S., Dumcius, S., Hjelte, L., Hoiby, N., et al. Chronic Pseudomonas aeruginosa infection definition: EuroCareCF Working Group report. J Cyst Fibros 10:Suppl. 2 (2011), S75–S78.
20. [20] Bell, S.C., Robinson, P.J., Cystic Fibrosis Standards of Care, Australia. North Ryde, Sydney, NSW, 2113. http://www.cysticfibrosis.org.au/media/wysiwyg/CF-Australia/PDF_files/CFA_Standards_of_Care_journal_31_Mar_08.pdf, 2008.
21. [21] Gilligan, P.H., Kiska, D.L., Appleman, M.D., Cumitech 43, Cystic Fibrosis Microbiology. 2006.
22. [22] Hankinson, J.L., Odencrantz, J.R., Fedan, K.B., Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med 159:1 (1999), 179–187.
23. [23] Wang, X., Dockery, D.W., Wypij, D., Fay, M.E., Ferris, B.G. Jr., Pulmonary function between 6 and 18 years of age. Pediatr Pulmonol 15:2 (1993), 75–88.
24. [24] Cystic fibrosis mutation database [21 January 2016]. Available from: http://www.genet.sickkids.on.ca/app.
25. [25] Clinical and Functional Translation of CFTR (CFTR2) website [21 January 2016]. Available from: http://www.cftr2.org/.
26. [26] Cystic Fibrosis Foundation Patient Registry, 2013 Annual Data report to the Center Directors. 2014, Cystitic Fibrosis Foundation, Bethesda, Maryland [www.cff.org/Our-Research/CF-Patient-Registry/].
27. [27] Green, D.M., McDougal, K.E., Blackman, S.M., Sosnay, P.R., Henderson, L.B., Naughton, K.M., et al. Mutations that permit residual CFTR function delay acquisition of multiple respiratory pathogens in CF patients. Respir Res, 11, 2010, 140.
28. [28] Burgel, P.R., Bellis, G., Olesen, H.V., Viviani, L., Zolin, A., Blasi, F., et al. Future trends in cystic fibrosis demography in 34 European countries. Eur Respir J 46:1 (2015), 133–141.
29. [29] VanDevanter, D.R., Rasouliyan, L., Murphy, T.M., Morgan, W.J., Ren, C.L., Konstan, M.W., et al. Trends in the clinical characteristics of the U.S. cystic fibrosis patient population from 1995 to 2005. Pediatr Pulmonol 43:8 (2008), 739–744.
30. [30] Bell, S.C., Reid, D.W., Challenges of the care of adults with cystic fibrosis. ERJ Monogr 64 (2014), 287–304.
31. [31] Smith, D.J., Ramsay, K.A., Yerkovich, S.T., Reid, D.W., Wainwright, C.E., Grimwood, K., et al. Pseudomonas aeruginosa antibiotic resistance in Australian cystic fibrosis centres. Respirology 21:2 (2016), 329–337.
32. [32] Parkins, M.D., Floto, R.A., Emerging bacterial pathogens and changing concepts of bacterial pathogenesis in cystic fibrosis. J Cyst Fibros 14:3 (2015), 293–304.
33. [33] Garske, L.A., Kidd, T.J., Gan, R., Bunting, J.P., Franks, C.A., Coulter, C., et al. Rifampicin and sodium fusidate reduces the frequency of methicillin-resistant Staphylococcus aureus (MRSA) isolation in adults with cystic fibrosis and chronic MRSA infection. J Hosp Infect 56:3 (2004), 208–214.
34. [34] Ramsay, K.A., Butler, C.A., Paynter, S., Ware, R.S., Kidd, T.J., Wainwright, C.E., et al. Factors influencing acquisition of Burkholderia cepacia complex organisms in patients with cystic fibrosis. J Clin Microbiol 51:12 (2013), 3975–3980.
35. [35] Zlosnik, J.E., Zhou, G., Brant, R., Henry, D.A., Hird, T.J., Mahenthiralingam, E., et al. Burkholderia species infections in patients with cystic fibrosis in British Columbia, Canada. 30 years’ experience. Ann Am Thorac Soc 12:1 (2015), 70–78.
36. [36] Desai, A.P., Stanley, T., Atuan, M., McKey, J., Lipuma, J.J., Rogers, B., et al. Use of matrix assisted laser desorption ionisation-time of flight mass spectrometry in a paediatric clinical laboratory for identification of bacteria commonly isolated from cystic fibrosis patients. J Clin Pathol 65:9 (2012), 835–838.